Carboplatin

Alkylating Agent
DB00958
Approved Indication

For the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide. It is also indicated for the palliative treatment of patients with ovarian carcinoma recurr

0 Targets
0 Resistance Mutations
3 References
3D Structure No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action

Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

Details
DrugBank ID DB00958 ↗
Approval Date 2004-10-14
Molecular Weight 371.254 g/mol
Drug Class Alkylating Agent
ATC Codes L01XA02
Synonyms Carboplatin, CBDCA
SMILES
N.N.O=C1O[Pt]OC(=O)C11CCC1
ADMET Profile
Computing properties…